Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates.

Literature DB >> 18922692

Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates.

Joshua D Thomas¹, Thomas Hofer, Christoph Rader, Terrence R Burke.

Abstract

A flexible, trifunctional poly(ethylene glycol)-succinamide-Lysine-Lysine-maleimide (PEG-SU-Lys-Lys-mal) linker was employed to simultaneously allow biotin tagging and cell-surface targeting through an integrin alpha(4)beta(1)-binding peptidomimetic that was regiospecifically conjugated to an IgG1-derived Fc fragment with an engineered C-terminal selenocysteine residue. The resulting antibody derivative mediates Fc receptor binding by virtue of the Fc protein and selectively targets cancer cells expressing human integrin alpha(4)beta(1). The PEG-SU-Lys-Lys-mal linker may have general utility as an organic tether for the construction of antibody-drug conjugates.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2008 PMID： 18922692 PMCID： PMC3461582 DOI： 10.1016/j.bmcl.2008.09.078

Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823

18 in total

1. Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors: Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal: Proc Natl Acad Sci U S A Date: 2003-04-17 Impact factor: 11.205

2. Synthesis of hydrophilic and flexible linkers for peptide derivatization in solid phase.

Authors: Aimin Song; Xiaobing Wang; Jinhua Zhang; Jan Marík; Carlito B Lebrilla; Kit S Lam
Journal: Bioorg Med Chem Lett Date: 2004-01-05 Impact factor: 2.823

3. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.

Authors: Joseph R Berger; Igor J Koralnik
Journal: N Engl J Med Date: 2005-06-09 Impact factor: 91.245

4. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.

Authors: Annette Langer-Gould; Scott W Atlas; Ari J Green; Andrew W Bollen; Daniel Pelletier
Journal: N Engl J Med Date: 2005-06-09 Impact factor: 91.245

5. Patients at risk.

Authors: Jeffrey M Drazen
Journal: N Engl J Med Date: 2005-06-09 Impact factor: 91.245

6. Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model.

Authors: Dian L Olson; Linda C Burkly; Diane R Leone; Brian M Dolinski; Roy R Lobb
Journal: Mol Cancer Ther Date: 2005-01 Impact factor: 6.261

Review 7. alpha 4 integrins and tumor metastasis.

Authors: B Holzmann; U Gosslar; M Bittner
Journal: Curr Top Microbiol Immunol Date: 1998 Impact factor: 4.291

8. Automated synthesis of N-bromoacetyl-modified peptides for the preparation of synthetic peptide polymers, peptide-protein conjugates, and cyclic peptides.

Authors: F A Robey; R L Fields
Journal: Anal Biochem Date: 1989-03 Impact factor: 3.365

9. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia.

Authors: Takuya Matsunaga; Naofumi Takemoto; Tsutomu Sato; Rishu Takimoto; Ikuta Tanaka; Akihito Fujimi; Takehide Akiyama; Hiroyuki Kuroda; Yutaka Kawano; Masayoshi Kobune; Junji Kato; Yasuo Hirayama; Sumio Sakamaki; Kyuhei Kohda; Kensuke Miyake; Yoshiro Niitsu
Journal: Nat Med Date: 2003-08-03 Impact factor: 53.440

10. An engineered selenocysteine defines a unique class of antibody derivatives.

Authors: Thomas Hofer; Joshua D Thomas; Terrence R Burke; Christoph Rader
Journal: Proc Natl Acad Sci U S A Date: 2008-08-21 Impact factor: 11.205

6 in total

Review 1. Chemically programmed antibodies.

Authors: Christoph Rader
Journal: Trends Biotechnol Date: 2014-03-11 Impact factor: 19.536